Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
When people first read about NK cell therapy, one of the earliest questions is simple: what could go wrong? Because the treatment uses your own immune cells, it is often described as gentle on the body. That description is a useful starting point, but it is not the whole picture. This article explains what is generally understood about reactions and risks, what remains uncertain, and which questions are worth bringing to a consultation at Grand Green Osaka Umekita Clinic or any other clinic you are considering.
The short answer: a gentle approach does not mean no risk
NK (natural killer) cells are immune cells that patrol the body and respond to cancer cells and virus-infected cells. In NK cell therapy, your own NK cells are obtained from a standard blood draw, activated and expanded at a specialized facility, and then returned to your body by IV infusion. Because the cells come from you, the risk of rejection is considered low, and serious side effects have rarely been reported. Even so, rarely reported is not the same as never, and every person responds differently.
A good consultation will not promise an outcome. It will explain what is known, what is not known, and how your own medical history changes the picture. That is the kind of conversation you should expect before you decide anything.
Reactions that may occur after infusion
The reactions most often mentioned in connection with autologous immune cell therapy are temporary ones. Some patients experience a short-lived fever or a feeling of fatigue after an infusion. Other reactions are also possible, including those related to the blood draw or the IV line, such as bruising or discomfort at the needle site. Whether a particular symptom is related to the therapy, to your underlying condition, or to your standard cancer treatment is not always obvious, which is why it helps to report everything to your care team.
- Temporary fever or chills after the infusion
- Fatigue or a general feeling of being unwell
- Discomfort or bruising where the needle was placed
- Any new or unusual symptom, which should be reported to a doctor promptly
Ask the clinic what symptoms they would want to hear about, how you can contact them after an infusion, and what the plan is if a reaction occurs. Clear answers to those practical questions say a lot about how a clinic manages safety.
Questions about combining NK cell therapy with standard treatment
NK cell therapy is not intended to replace surgery, chemotherapy, or radiation therapy. It is generally described as something that can be considered alongside them, and a clinic can coordinate with the medical institution providing your standard treatment. Still, the timing and your current health matter. Your blood counts, your treatment schedule, and any medicines you take can all influence what is appropriate for you.
Before you start, consider asking your oncologist whether they have concerns about adding an immune cell therapy, and share their answer with the doctor who will be performing the NK cell therapy. Keeping both teams informed reduces the chance of surprises and keeps your standard treatment at the center of your care.
What is still uncertain about the evidence
Research on NK cell-based immunotherapy is ongoing, and published studies vary in the type of cancer, the way cells are prepared, the dose, and the way results are measured. Findings from one study should not be generalized to every patient. It is reasonable to ask a doctor which studies or public information they rely on, how those findings apply to your situation, and what the limits are. You can also search PubMed yourself and bring questions to your appointment.
Be cautious of any explanation that sounds certain. Immune cell therapy is a treatment option worth understanding, but it does not guarantee a particular result, and responses differ from person to person.
Self-pay treatment, legal framework, and cell quality
In Japan, NK cell therapy is provided as a self-pay treatment, which means it is not covered by national health insurance. It is offered under Japan’s Act on the Safety of Regenerative Medicine, which requires a provision plan to be submitted to and accepted by the authorities and requires cells to be processed at an appropriately licensed facility. These rules exist to support safety management, but they do not remove the need for your own careful review.
- Is the treatment provided under a plan accepted under the Act on the Safety of Regenerative Medicine?
- Where are the cells processed, and how is quality controlled?
- What is the total cost, how many infusions are proposed, and over what period?
- What are the known risks, and what happens if you wish to stop?
Costs, number of sessions, risks, side effects, and whether the therapy is suitable for you all need to be confirmed in a medical consultation. Do not rely on a general article, including this one, to make that decision.
Preparing for a consultation in Osaka
If you are in Osaka, living in Japan as a foreign resident, or considering traveling for medical care, Grand Green Osaka Umekita Clinic in the Umeda area offers consultations about NK cell therapy and provides information pages in several languages. Language support can be especially important when you are discussing risks and consent, so it is worth confirming in advance how interpretation and written materials will be handled.
Bring your diagnosis, a summary of your current treatment, a list of medicines, and your questions in writing. If you are traveling, ask how follow-up would work after you return home and how information can be shared with your doctors there.
Key points to take away
NK cell therapy uses your own cells and is generally described as having few serious side effects, but temporary reactions such as fever or fatigue can occur, and evidence is still developing. It is a self-pay treatment provided under Japanese regulation, and it is meant to be considered alongside, not instead of, standard cancer care. The most useful step is a thorough consultation in which a doctor explains the benefits, limits, risks, and costs in the context of your own health. Prepare your questions, share information with all of your doctors, and take the time you need to decide.
- Know possible reactionsTemporary fever or fatigue
- Alongside standard careNot a replacement
- Self-pay and regulatedConfirm plan and facility
- Ask a doctorRisks, costs, suitability
This diagram is a conceptual summary of the article content
References
- PubMed: Optimizing CAR-NK Cell Transduction and Expansion: Leveraging Cytokine Modulation for Enhanced Performance. (2024)
- PubMed: Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. (2026)
- PubMed: Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. (2020)
- PubMed: A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma. (2022)
- PubMed: CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. (2023)
- PMC: Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. (2013)
- PMC: Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. (2022)
- PMC: Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. (2023)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.